ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Insider buying today :

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Jun 23, 2022 12:14pm

152 Views

Post# 34777391

RE:Insider buying today :

There is the volume for today ..

Recent filings
2022-06-2308:44 2022-06-23	$PMN	Kirwin, Patrick D. 4 - Director of Issuer Holder: Patrick D Kirwin Professional Corporation (Indirect Ownership)	Common Shares 10 - Acquisition or disposition in the public market	$23,000 +200,000vol $0.115each	1,339,900
2022-06-2308:40 2022-06-23	$PMN	Williams, Eugene Warren 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$49,450 +500,000vol $0.0989each	8,503,816